[1]乔 君,高 翔,王 瑜,等.缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响[J].医学信息,2018,31(07):65-68.[doi:10.3969/j.issn.1006-1959.2018.07.021]
　QIAO Jun,GAO Xiang,WANG Yu,et al.The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(07):65-68.[doi:10.3969/j.issn.1006-1959.2018.07.021]
点击复制

缬沙坦对原发性高血压患者外周PBMC中IL-17表达的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年07期
页码:
65-68
栏目:
论著
出版日期:
2018-04-01

文章信息/Info

Title:
The Effect of Valsartan on the Expression of IL-17 in Peripheral PBMC of Patients with Essential Hypertension
文章编号:
1006-1959（2018）07-0065-04
作者:
乔 君1; 2; 高 翔3; 王 瑜1; 梅仁彪1
1.安徽理工大学医学院医学机能学教研室，安徽 淮南 232001； 2.淮南市第二人民医院检验科，安徽 淮南 232072； 3.淮南市第二人民医院内科，安徽 淮南 232072
Author(s):
QIAO Jun1; 2; GAO Xiang3; WANG Yu1; MEI Ren-biao1
1.Department of Medical Science and Research,Anhui University Of Science and Technology Medical College,Huainan 232001,Anhui,China; 2.Department of Laboratory,Huainan Second People's Hospital,Huainan 232072,Anhui,China; 3.Department of Internal Medicine,Huainan Second People's Hospital,Huainan 232072,Anhui,China
关键词:
缬沙坦; 高血压; IL-17
Keywords:
Key words：Valsartan; Hypertension; IL-17
分类号:
R544.1
DOI:
10.3969/j.issn.1006-1959.2018.07.021
文献标志码:
A
摘要:
目的 探讨血管紧张素Ⅱ受体阻滞剂缬沙坦对高血压患者外周血单核细胞中IL-17表达的影响。方法 选取2016年9月~2017年10月在我院收治的原发性高血压患者98例，将所有患者按照随机数字表法分为缬沙坦组和硝苯地平组，各49例，缬沙坦组患者使用缬沙坦治疗，硝苯地平组患者使用硝苯地平缓释片治疗，另选取健康体检者20例为正常组。采集患者治疗前及治疗4周后静脉血，分离PBMC体外培养5 h后用RT-PCR法测定IL-17 mRNA表达水平；培养上清液采用ELISA法测定IL-17浓度。结果 治疗4周后缬沙坦组与硝苯地平组血压变化比较，差异无统计学意义（P＞0.05）；缬沙坦组治疗后PBMC中IL-17 mRNA表达及培养上清液中IL-17浓度分别为（0.29±0.09），（76.16±20.56）pg/ml，低于硝苯地平组的（0.50±0.15），（137.84±39.97)pg/ml，组间比较，差异有统计学意义（P＜0.05）。结论 缬沙坦可显著降低高血压患者PBMC中IL-17的表达，有助于延缓疾病发展。
Abstract:
Abstract：Objective To investigate the effect of valsartan, an angiotensinⅡreceptor blocker,on the expression of IL-17 in peripheral blood monocytes of patients with hypertension.Methods 98 patients with essential hypertension admitted in our hospital from September 2016 to October 2017 were randomly divided into valsartan group and nifedipine group(49 cases each).Patients in valsartan group were treated with valsartan,nifedipine group was treated with nifedipine sustained release tablet,and 20 healthy cases were selected as normal group.Venous blood was collected before and after 4 weeks of treatment.The expression of IL-17 mRNA was measured by RT-PCR method after 5 h culture of PBMC in vitro,and the IL-17 concentration was measured by ELISA method in the supernatant of culture supernatant.Results After 4 weeks of treatment, there was no significant difference in blood pressure between valsartan group and nifedipine group,the difference was not statistically significant(P>0.05),the IL-17 mRNA expression in PBMC and the concentration of IL-17 in the culture supernatant of the valsartan group were(0.29±0.09),(76.16±20.56)pg/ml,respectively,lower than that of the nifedipine group(0.50±0.15),(137.84±39.97)pg/ml,the difference between the groups was statistically significant(P<0.05).Conclusion Valsartan can significantly reduce the expression of IL-17 in the PBMCs of hypertensive patients and help to delay the development of the disease.

参考文献/References:

[1]Agabiti-Rosei E,Heagerty AM,Rizzoni D.Effects of antihypertensive treatment on small artery remodelling[J].J Hypertens,2009,27(6):1107-1114. [2]Boutouyrie P,Lacolley P,Briet M,et al.Pharmacological modulation of arterial stiffness[J].Drugs,2011,71(13):1689-1701. [3]Laurent S,Boutouyrie P.Dose-dependent arterial destiffening and inward remodeling after olmesartan in hypertensives with metabolic syndrome[J].Hypertension,2014,64(4):709-716. [4]Jiang Y,Wang HY,Zheng S,et al.Cardioprotective effect of valsartan in mice with short-term high-salt diet by regulating cardiac aquaporin 1 and angiogenic factor expression[J].Cardiovasc Pathol,2015,24(4):224-229. [5]Saleh MA,Norlander AE,Madhur MS.Inhibition of Interleukin 17-A but not Intereukin-17F Signaling Lowers Blood Pressure and Reduces End-organ Inflammation in Angiotensin Ⅱ-induced Hypertension[J].JACC Basic Transl Sci,2016,1(7):606-616. [6]Norlander AE,Saleh MA,Kamat NV,et al.Interleukin-17A regulates renal sodium transporters and renal injury in Angiotensin Ⅱ-induced hypertension[J].Hypertension,2016,68(1):167-174.

相似文献/References:

[1]颜 明,龚丽娜,王淑清.彩超在高血压患者肾动脉血流动力学检测中的应用分析[J].医学信息,2018,31(02):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
　YAN Ming,GONG Li-na,WANG Shu-qing.Application of Color Doppler Ultrasound in the Measurement of Renal Artery Hemodynamics in Patients with Hypertension[J].Journal of Medical Information,2018,31(07):156.[doi:10.3969/j.issn.1006-1959.2018.02.060]
[2]夏能能,任 薇,杜建平,等.1953~2016年中医药治疗高血压领域研究热点分析[J].医学信息,2018,31(04):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
　XIA Neng-neng,REN Wei,DU Jian-ping,et al.Analysis of Hot Spots in the Research of Traditional Chinese Medicine in Treating Hypertension from 1953 to 2016[J].Journal of Medical Information,2018,31(07):18.[doi:10.3969/j.issn.1006-1959.2018.04.007]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(07):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]董巧玲.健康教育对原发性高血压患者治疗效果的影响[J].医学信息,2018,31(09):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
　DONG Qiao-ling.Effect of Health Education on Treatment of Patients with Essential Hypertension[J].Journal of Medical Information,2018,31(07):180.[doi:10.3969/j.issn.1006-1959.2018.09.060]
[5]汤海霞,班 涛.大黄素与心血管疾病的研究[J].医学信息,2022,35(11):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
　TANG Hai-xia,BAN Tao.Research on Emodin and Cardiovascular Diseases[J].Journal of Medical Information,2022,35(07):19.[doi:10.3969/j.issn.1006-1959.2022.11.006]
[6]沈 正,王庆海.焦虑抑郁障碍与血压变异性研究[J].医学信息,2018,31(16):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
　SHEN Zheng,WANG Qing-hai.Study on Anxiety and Depression Disorder and Blood Pressure Variability[J].Journal of Medical Information,2018,31(07):34.[doi:10.3969/j.issn.1006-1959.2018.16.010]
[7]左洪亮.苯磺酸左旋氨氯地平片治疗中老年患者 轻中度原发性高血压的疗效观察[J].医学信息,2018,31(16):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
　ZUO Hong-liang.Efficacy of Levamlodipine Besylate Tablets in Treatment of Mild to Moderate Essential Hypertension in Middle-aged and Elderly Patients[J].Journal of Medical Information,2018,31(07):120.[doi:10.3969/j.issn.1006-1959.2018.16.037]
[8]袁 敏,周袁成.钙离子拮抗剂类降压药的临床应用与不良反应分析[J].医学信息,2018,31(17):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
　YUAN Min,ZHOU Yuan-cheng.Clinical Application and Adverse Reaction Analysis of Calcium Antagonist Antihypertensive Drugs[J].Journal of Medical Information,2018,31(07):125.[doi:10.3969/j.issn.1006-1959.2018.17.038]
[9]陈学军,李 敏,张 丹,等.社区一体化分级管理模式对社区老年高血压患者的管理效果[J].医学信息,2018,31(18):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
　CHEN Xue-jun,LI Min,ZHANG Dan,et al.Management Effect of Community Integration Hierarchical Management Mode on Elderly Hypertensive Patients in Community[J].Journal of Medical Information,2018,31(07):169.[doi:10.3969/j.issn.1006-1959.2018.18.055]
[10]张莉莉.左旋氨氯地平和氨氯地平治疗轻中度高血压临床效果观察[J].医学信息,2018,31(21):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]
　ZHANG Li-li.Clinical Efficacy of Levamlodipine and Amlodipine in Treatment of Mild to Moderate Hypertension[J].Journal of Medical Information,2018,31(07):149.[doi:10.3969/j.issn.1006-1959.2018.21.043]
[11]张成杰,安庆华,郑玉明,等.苯磺酸左旋氨氯地平与缬沙坦对高血压患者脂质代谢和系统性应激的影响[J].医学信息,2020,33(21):140.[doi:10.3969/j.issn.1006-1959.2020.21.043]
　ZHANG Cheng-jie,AN Qing-hua,ZHENG Yu-ming,et al.Effects of Levamlodipine Besylateand Valsartan on Lipid Metabolism and Systemic Stress in Patients with Hypertension[J].Journal of Medical Information,2020,33(07):140.[doi:10.3969/j.issn.1006-1959.2020.21.043]

更新日期/Last Update: 2018-04-01